Any BioTech Guys that Have Looked at Moderna?

I am not a biotech person, looking at Moderna. Has any looked at Moderna as a possible long or short? Why was it USED for such an IMPORTANT pandemic? Specifically trying to get comfortable with the following qs: 

1. Which of their drugs in-development are first-in-class drugs? What is generally the decision-framework behind allocating capital to these? 

2. How does one think through their scientist research and your scientist-retention ratio? What is the best way to measure productivity? Is it increase (%) in R&D relative to the % # of drugs that pass onto the next phase?    

3. I am looking at their teams' cost-base in relation to Pfitzer (much larger company, granted), and using your SG&A expense as a proxy for fixed costs including non R&D salaries, I see the average cost / employee is $110K compared to $73K for Pfitzer. I understand earlier years may be spent burning cash, but Moderna has been around for 10+ years now. How do I justify these to myself? 

4. Related to the above note, for the senior management, how is the payout determined? What factor does R&D pipeline achievement play in that?     

5. With respect to its revenue split, how should one think about it from Government Contracts, and Grant perspective, and which r assets have licensing potential i.e. ability to earn royalties? 

6. Their revenue for 9M 21 was about $11.3 billion, of which 75% is in deferred revenue. What would be the cost of servicing this revenue? Is it non-material?

7. I am not a fan of DCFs, particularly over a long time frame. It's like coming up with something out of your ass when you have no idea what will transpire over the future. What's a better valuation metric to value biotech?

8. For those of you with non science backgrounds, how did you get comfortable "understanding the science"?

Let me know pls. thx 

2 Comments
 
 

Id debitis nostrum cumque perspiciatis id autem. Quidem rem neque molestias repellat laborum accusantium accusantium.

Quae a eum dolorem est alias error neque. Saepe recusandae nulla libero corporis eos sint qui. Ut reprehenderit qui atque autem omnis sit maiores. A labore accusamus deleniti sit aut ratione recusandae. Quis laboriosam esse aliquid qui cupiditate temporibus aliquam. Incidunt minima ducimus cupiditate inventore.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.9%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 03 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (53) $259
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (15) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
Betsy Massar's picture
Betsy Massar
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
bolo up's picture
bolo up
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”